Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
10 April 2023 - 8:50PM
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG)
(“
Bright Minds” or the
“
Company”), a biotechnology company focused on
developing novel drugs for the targeted treatment of
neuropsychiatric disorders, epilepsy, and pain, today announced
that Alex Vasilkevich, Bright Minds’ Scientific Officer, will
present at the 20th International Meeting of the International
Society for Serotonin Research (ISSR). The ISSR, a nonprofit
founded in 1987, is a professional association for biomedical
scientists interested in research involving the neurotransmitter
serotonin (5-hydroxytryptamine).
Mr. Vasilkevich’s presentation, entitled “BMB-101: A selective
5-HT2C agonist in clinical trials with therapeutic utility,” is
part of the “Novel class of 5-HT2C agonists with therapeutic
promise and novel signaling mechanisms” program, chaired by John
McCorvy, PhD, Senior Advisor to Bright Minds.
“We are pleased to participate in this important conference and
to share the progress of BMB-101 with other dedicated scientists
studying serotonin. This is an exciting opportunity to engage with
thought leaders in this space and to build awareness of our
approach to the potential treatment of multiple mental health
disorders that stem from dysfunction in the serotonin system.
Compared to Lorcaserin, BMB-101 exhibits strong Gq signaling
coupled with minimal beta-arrestin recruitment. Bright Minds is
committed to advancing its clinical programs with the hope of
changing the treatment paradigm for mental health disorders,”
stated Alex Vasilkevich, Scientific Officer at Bright Minds.
BMB-101 is a highly selective and potent 5-HT2C agonist that has
entered first-in-human Phase I clinical evaluation. The trial is
being conducted in Adelaide, Australia, by CMAX Clinical Research,
a clinical trial center specializing in a range of early-phase
trials and first-in-human studies. It is a three-part study to
evaluate the safety, tolerability, pharmacokinetic (PK), and food
effect in healthy volunteers. BMB-101 has demonstrated compelling
activity in a host of in vitro and in vivo non-clinical tests.
About BMB-101
BMB-101, a 5-HT2C selective and biased agonist, has demonstrated
compelling activity in a host of in vitro and in vivo non-clinical
tests. Compared to Lorcaserin, BMB-101 exhibits strong Gq signaling
coupled with minimal beta-arrestin recruitment. Mechanistically,
Serotonin (5-Hydroxytryptamine, 5-HT) is a monoamine
neurotransmitter widely expressed in the central nervous system,
and drugs modulating 5-HT have made a major impact in mental health
disorders. Central 5-HT systems have long been associated with the
control of ingestive behaviors and the modulation of the behavioral
effects of psychostimulants, opioids, alcohol and nicotine. Results
of clinical trials and animal studies indicate that 5-HT2C receptor
agonists may have therapeutic potential in the treatment of
addiction by decreasing the intake of opioids as well as impulsive
behavior that can escalate compulsive drug use.
5-HT2C receptors are considered to be involved in epileptiform
activity and its activation is thought to have anticonvulsant
properties. In well-established and predictive animal models,
BMB-101 demonstrated a significant reduction in both the number and
intensity of epileptic seizures and is a promising candidate for
the treatment of Dravet Syndrome and other forms of epilepsies.
BMB-101 is currently being evaluated in a Phase I trial (NCT
05397041) designed to assess the compound's safety, tolerability,
pharmacokinetics, and food effect in healthy volunteers.
About Bright Minds
Bright Minds is focused on developing novel
transformative treatments for neuropsychiatric disorders, epilepsy,
and pain. Bright Minds has a portfolio of next-generation serotonin
agonists designed to target neurocircuit abnormalities that are
responsible for difficult to treat disorders such as resistant
epilepsy, treatment resistant depression, PTSD, and pain. The
Company leverages its world-class scientific and drug development
expertise to bring forward the next generation of safe and
efficacious drugs. Bright Minds’ drugs have been designed to
potentially retain the powerful therapeutic aspects of psychedelic
and other serotonergic compounds, while minimizing the side
effects, thereby creating superior drugs to first-generation
compounds, such as psilocybin.
Investor Contacts:Lisa WilsonE:
lwilson@insitecony.comT: 917-543-9932
Ian McDonaldCEO and DirectorE:
ian@brightmindsbio.comT: 917-543-9932
This news release includes certain statements
that may be deemed “forward-looking statements.” All statements in
this new release, other than statements of historical facts, that
address events or developments that the Company expects to occur,
are forward-looking statements. Forward-looking statements are
statements that are not historical facts and are generally, but not
always, identified by the words “expects,” “plans,” “anticipates,”
“believes,” “intends,” “estimates,” “projects,” “potential,” and
similar expressions, or that events or conditions “will,” “would,”
“may,” “could,” or “should” occur. Forward-looking information in
this news release includes statements related to the continuation
of three phases of clinical trials related to BMB-101, and the
Company’s attendance at the International Meeting of the
International Society for Serotonin Research. Although the Company
believes the expectations expressed in such forward-looking
statements are based on reasonable assumptions, such statements are
not guarantees of future performance and actual results may differ
materially from those in the forward-looking statements. Factors
that could cause the actual results to differ materially from those
in forward-looking statements include market prices, continued
availability of capital and financing, results of clinical trials
with respect to each of BMB-101 and BMB-202, regulatory conditions
with respect to in-human drug trials, and general economic, market
or business conditions. Investors are cautioned that any such
statements are not guarantees of future performance and actual
results or developments may differ materially from those projected
in the forward-looking statements. Forward-looking statements are
based on the beliefs, estimates and opinions of the Company’s
management on the date the statements are made. Except as required
by applicable securities laws, the Company undertakes no obligation
to update these forward-looking statements in the event that
management's beliefs, estimates or opinions, or other factors,
should change.
Neither the Canadian Securities Exchange nor its
Regulation Services Provider accepts responsibility for the
adequacy or accuracy of this release.
Bright Minds Biosciences (NASDAQ:DRUG)
Historical Stock Chart
From May 2024 to Jun 2024
Bright Minds Biosciences (NASDAQ:DRUG)
Historical Stock Chart
From Jun 2023 to Jun 2024